IRB Services awarded full accreditation by AAHRPP

Wednesday, December 21, 2011 12:42 PM

Institutional Review Board Services (IRB Services) has been awarded full accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).

IRB Services is the first fully independent, unaffiliated Canadian-based research ethics committee to earn Accreditation from AAHRPP.

Founded in 1993, IRB Services is an independent organization dedicated to protecting the rights and safety of human subjects. IRB Services operates research ethics committees in Toronto, Ontario; Montreal, Quebec; and Boca Raton, Florida, which review a wide range of both industry and publicly funded human subject research across multiple disciplines, including Health Canada, Food and Drug Administration, and US Department of Health and Human Services regulated research.

“Since IRB Services operates in an international environment with geographically-dispersed ethics committees dealing with a complex matrix of regulatory and ethical requirements, AAHRPP’s accreditation process has ensured the company meets or exceeds all those obligations and more,” said Jack Corman, president and CEO of IRB Services.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs